Longenesis
Longenesis is a Latvian health-tech SaaS provider offering Engage (patient engagement and dynamic consent) and Curator (anonymized biomedical data discovery) platforms to biopharma, biobanks, hospitals, and medical device companies across Europe and the Middle East, enabling cohort identification and real-world evidence generation.
- Company typePrivate
- Founded2017
- HeadquartersRiga, Latvia
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Longenesis does
Longenesis (legal entity SIA Longenesis, headquartered at Dzirnavu iela 41a-5, Riga, Latvia) is a private health-technology SaaS company founded around 2017 that builds digital platforms for biomedical research and patient engagement. Its two flagship products are Engage, a patient engagement platform offering dynamic consent, e-consent, screening tools, PROMs/PREMs surveys, risk stratification calculators, and patient diaries; and Curator, a biomedical research acceleration platform that lets biobanks, hospitals, registries, and biotech companies publish anonymized metadata and enables real-time patient cohort identification against inclusion/exclusion criteria. The technology stack is cloud-based and certified to ISO/IEC 27001 and ISO/IEC 27701 with full GDPR compliance, positioning the product for regulated healthcare environments.
The company sells tiered annual and multi-year SaaS subscriptions alongside project-based engagements, with a freemium nonprofit onboarding funnel for Curator and a direct enterprise sales motion. Target customers span biopharma and biotech (Medtronic, Gedeon Richter, Ewopharma, Dante Genomics), biobanks and registries, hospitals and academic medical centers (Children's Clinical University Hospital Latvia, Pauls Stradins Clinical University Hospital, Riga Stradins University, Latvian BMC), and national health programs — most prominently the M42 Health Emirati Genome Programme in the UAE, which has engaged 500,000+ citizens since 2020. Distribution combines direct enterprise sales, partnership-led co-development with biopharma and genomics players, and self-service Curator registration, supported by AWS infrastructure and an EIT Health partnership.
To date Longenesis has raised approximately $1.3 million across a $1.2 million late seed round in June 2021 led by Rustam Gilfanov and a $100,000 Supernova Challenge grant in October 2024, with no Series A disclosed. Its growth strategy relies heavily on EU Cohesion Policy and Latvia Recovery and Resilience Facility-funded co-development projects (cardiometabolic, Type 1 diabetes via DiaBuddy, cardiology, rare skin disease) alongside commercial contracts, keeping headcount in the 11–50 range while expanding its therapeutic-area focus and geographic footprint across the Baltics, Central and Eastern Europe, the Mediterranean, and the Middle East.
Longenesis firmographics
Firmographics- Name
- Longenesis
- Legal name
- SIA Longenesis
- Website
- https://longenesis.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Longenesis is a Latvian health-tech SaaS provider offering Engage (patient engagement and dynamic consent) and Curator (anonymized biomedical data discovery) platforms to biopharma, biobanks, hospitals, and medical device companies across Europe and the Middle East, enabling cohort identification and real-world evidence generation.
- Ownership category
- akta.pro rank
Longenesis industry classification
Industry- Product category
- Clinical Trial Technology / Healthcare Research Software
- NAICS
- Software Publishers (513210)
- SIC
- Services-Computer Programming, Data Processing, Etc. (7370)
- akta.pro primary industry
- Site & Investigator Platforms (Site Payments, Feasibility, Activation) (HLACAOAJ)
- akta.pro secondary industry
- Patient Engagement, Education & Messaging Platforms (portal/CRM integrated) (HLALABAJ)
Keywords
Where Longenesis is headquartered
LocationHeadquarters
- HQ city
- Riga
- HQ country
- Latvia
- HQ region
- Europe
Offices1 record
Markets served
Longenesis business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- SaaS Platform Subscriptions: Longenesis operates as a SaaS company offering subscription-based access to its Engage and Curator platforms. The revenue model involves tiered pricing for different user roles (Data Publisher, Collaborator, or both) with annual or multi-year subscription contracts typical for enterprise customers.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Freemium | Monthly | Free Trial for Nonprofits |
| Subscription | Annual | Data Publisher Plan |
| Subscription | Annual | Collaborator Plan |
| Subscription | Multi-year contract | Data Publisher and Collaborator Plan |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
Longenesis product offering
Product offeringCore offering
Longenesis provides a dual SaaS platform ecosystem for biomedical research and patient engagement. Engage is a digital patient engagement platform offering dynamic consent management, surveys, screening, PROMs/PREMs collection, patient diaries, and risk stratification tools. Curator is a biomedical research acceleration platform that lets biobanks, registries, and hospitals publish anonymised dataset metadata and enables researchers to query, identify patient cohorts, and request collaborations in real time, while preserving patient privacy and GDPR compliance.
Product overview
Longenesis is a SaaS company offering a digital platform for post-market research and patient engagement that bridges life-science companies, healthcare providers, and patients. The product portfolio consists of two flagship platforms: Engage and Curator. Engage is a patient engagement platform providing tools for e-consent, digital surveys, screening, patient-reported outcomes (PROMs/PREMs), patient identification, registries, and before/after visit monitoring. Curator is a biomedical research acceleration platform enabling data publishers (biobanks, hospitals, registries) to publish anonymised metadata for collaboration discovery, and allowing collaborators (researchers, pharma sponsors) to query and request access to datasets. These platforms are designed to be complementary—Curator serves as a mechanism for prospective data generation and cohort identification, while Engage facilitates direct patient engagement and data collection.
Differentiator
Problem solved
Functional benefit
Brands
- Engage: Digital patient engagement platform for research execution, consent management, patient onboarding, surveys, screening, and feedback activities.
- Curator
Products and services
- Curator Biomedical research acceleration platform that enables clinical investigators, patient organisations, registries, and biobanks to publish anonymised dataset metadata and showcase the scope of their data for research without compromising patient privacy. Collaborators can browse anonymised datasets, run advanced queries by inclusion/exclusion criteria, identify patient cohorts in real time, and send collaboration requests to data publishers. Targeted at biobanks, registries, hospitals, biopharma, and academic researchers.
- Engage Digital patient engagement and clinical research execution platform providing disease-specific tools including dynamic consent management, e-consent, surveys, screening and feedback activities, risk stratification calculators, patient diaries, reminders, and PROMs/PREMs collection. Designed to enable proactive engagement of patients and population cohorts in clinical research, market access, and adherence programs for biopharma, medical device, hospital, and academic customers.
- skrinings.lv Online health platform developed by Longenesis specialists that empowers individuals to learn about their health, particularly breast cancer risks and contraception methods, through tools such as a breast cancer risk assessment test. Integrates with Dante Genomics to offer discounted whole genome sequencing. Targeted at individual consumers seeking self-administered health screening.
Quantifiable outcome
- 500,000+ citizens participated in Emirati Genome Programme with Longenesis tools since 2020, expected to reach 1 million by 2025
- +2 more outcomes
Companies that use Longenesis
Customer profileNamed customers11 records
Segments6 records
Ideal customer profiles4 records
Longenesis technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Longenesis partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered core and flagship.
- Dante GenomicscorePartnership to offer whole genome sequencing (WGS) to more than 10,000 existing Longenesis study participants across the Baltics and Mediterranean regions. Dante Genomics provides at-home blood collection kits for WGS and genomic reports, while Longenesis enriches its digital educational engagement platform with discounted Dante offerings. The collaboration aims to make personalized medicine more mainstream across Europe.
- M42 Health (formerly G42 Healthcare)flagshipPartnership with M42 Health for the Emirati Genome Programme aims to create one of the world's largest patient biobanks. Longenesis provides digital tools for participant engagement and consent-driven medical research, while M42 Health contributes AI-powered healthcare capabilities and genomic sequencing expertise. The collaboration supports UAE's national genome initiative with over 500,000 citizens participating since 2020.
- MedtroniccoreCollaboration with Medtronic for implementing patient engagement solutions. Longenesis tools have impacted the speed of patient enrolment while complying with highest requirements of safety, data protection and participant-centricity. The partnership focuses on market access and patient enrollment for medical device research.
- EwopharmacorePartnership with Swiss pharmaceutical company Ewopharma for observational multicenter clinical trial into respiratory tract infections in children. Longenesis provides digital engagement tool, e-consent, patient diary and reminder functionality through its Engage platform to streamline data collection for investigators and participants' parents.
- Gedeon RichtercorePartnership with Hungarian pharmaceutical company Gedeon Richter for Real-World Data study on contraception. Longenesis.Curator platform enabled quick patient identification fitting inclusion criteria within existing cohort and immediate invitation sending for study participation.
- Riga Technical UniversitycoreResearch partnership with Riga Technical University for cardiometabolic disease digital platform project. EU Cohesion Policy funded project 1.1.1.3/1/24/A/090 developing cloud-based module for cardiometabolic disease prevention and early diagnosis.
- Pauls Stradiņš Clinical University HospitalcoreOngoing research collaboration with Pauls Stradiņš Clinical University Hospital on multiple projects including cardiometabolic disease prevention platform and DiaBuddy digital assistant for Type 1 diabetes patients.
- MEDONcorePartnership with MEDON for developing modular digital platform for clinical observations and research in cardiology. Project F-DIGIT-4 focuses on study design creation, patient engagement, and data analysis functionality.
- Children's Clinical University Hospital (Latvia)coreLong-term collaboration for patient surveys, long COVID symptom tracking in children, and PREM data gathering. Hospital has been using Longenesis digital tools for over a year with positive feedback on availability, speed, and development.
- Riga Stradiņš UniversitycoreAcademic partnership for Myasthenia gravis digital registry transformation and other research projects including rare skin diseases registry with Department of Atomic Physics and Spectroscopy.
Scale indicators8 records
Recent moves6 records
Expansion highlights6 records
Longenesis competitors and assessment
Company assessmentDirect peers
- Castor: Castor is a direct competitor offering an eClinical platform for decentralized and hybrid clinical trials, including eConsent, ePRO, and remote data capture. It overlaps directly with Longenesis Engage on patient engagement and consent management in clinical research.
- Medable: Medable provides a decentralized clinical trial platform with eCOA, eConsent, telehealth, and patient engagement tools. It competes head-to-head with Longenesis Engage for the same life sciences and CRO buyers running modern clinical studies.
- Signant Health: Signant Health specializes in clinical trial patient engagement, eCOA, ePRO, and rater training. Its product set directly competes with Longenesis Engage for pharma and CRO customers running patient-centric studies.
- TriNetX: TriNetX operates a global health research network that enables cohort identification and real-world data queries for clinical trial feasibility. It is the most direct competitor to Longenesis Curator for sponsor and CRO cohort discovery.
Broad incumbents
- Veeva Systems: Veeva offers a broad suite of cloud software for life sciences, including Vault Clinical (EDC, CTMS, eTMF) and CRM. It is a broad incumbent whose Vault platform can absorb functionality that overlaps with both Engage and Curator.
- Medidata (Dassault Systèmes): Medidata is a leading clinical trials technology platform covering EDC, CTMS, eCOA, randomization, and trial design. It is a broad incumbent whose Rave platform competes with Longenesis across the full clinical operations stack.
- Oracle Clinical One: Oracle's Clinical One platform is a unified clinical trial suite covering EDC, RTSM, eCOA, and patient engagement. It competes as a broad incumbent offering an end-to-end alternative to Longenesis's two-product approach.
- IQVIA: IQVIA combines clinical research services with technology platforms (e.g., EDC, eCOA, real-world data) and operates a large healthcare data network. It is a broad incumbent whose analytics and data network partially overlap with Curator's data discovery use cases.
Emerging players
- Y-Prime: Y-Prime provides clinical trial technology, including IRT, eCOA, and patient engagement tools, focused on simplifying trial operations. It is an emerging peer with overlapping capabilities to Longenesis Engage in the patient engagement and data collection layer.
- Florence Healthcare: Florence Healthcare provides an eRegulatory and site document management platform for clinical trials. While narrower than Longenesis, it competes in the same site- and study-management buying cycle that Longenesis targets with its research workflow tools.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Longenesis social profiles
Digital presenceLongenesis compliance and trust
Trust signalCompliance3 records
Longenesis financial estimates
Financial estimateRevenue estimate
Valuation estimate
Longenesis leadership team
Management profileNumber of profiles
Profiles9 records
Longenesis funding detail
Funding detailFunding overview
Funding rounds3 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Longenesis M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Longenesis
What does Longenesis do?
Longenesis provides a dual SaaS platform ecosystem for biomedical research and patient engagement. Engage is a digital patient engagement platform offering dynamic consent management, surveys, screening, PROMs/PREMs collection, patient diaries, and risk stratification tools. Curator is a biomedical research acceleration platform that lets biobanks, registries, and hospitals publish anonymised dataset metadata and enables researchers to query, identify patient cohorts, and request collaborations in real time, while preserving patient privacy and GDPR compliance.
Is Longenesis a public or private company?
Longenesis is a private company. It is classified as venture growth investor backed and is currently operating.
When was Longenesis founded?
Longenesis was founded in 2017. It employs 11 to 50 people.
Where is Longenesis based?
Longenesis is headquartered in Riga, Latvia, in the Europe region.
How does Longenesis make money?
One revenue line is on record: saaS Platform Subscriptions.
Who are Longenesis's main competitors?
Direct peers on record are Castor, Medable, Signant Health and TriNetX. Broad incumbents are Veeva Systems, Medidata (Dassault Systèmes), Oracle Clinical One and IQVIA. Emerging players are Y-Prime and Florence Healthcare.
Does Longenesis have an API?
No public API is recorded for Longenesis.
What industry is Longenesis in?
Longenesis's product category is Clinical Trial Technology / Healthcare Research Software. Its primary akta.pro industry code is HLACAOAJ, Site & Investigator Platforms (Site Payments, Feasibility, Activation), with a secondary code of HLALABAJ, Patient Engagement, Education & Messaging Platforms (portal/CRM integrated). Its NAICS code is 513210 and its SIC code is 7370.